EA201892249A1 - Конъюгированный ингибитор c1-эстеразы и пути его применения - Google Patents

Конъюгированный ингибитор c1-эстеразы и пути его применения

Info

Publication number
EA201892249A1
EA201892249A1 EA201892249A EA201892249A EA201892249A1 EA 201892249 A1 EA201892249 A1 EA 201892249A1 EA 201892249 A EA201892249 A EA 201892249A EA 201892249 A EA201892249 A EA 201892249A EA 201892249 A1 EA201892249 A1 EA 201892249A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugated
inh
applications
esterase inhibitor
present
Prior art date
Application number
EA201892249A
Other languages
English (en)
Inventor
Кевин Холмс
Анджела В. Нортон
Кларк Пан
Original Assignee
Шайр Хьюман Дженетик Терапиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шайр Хьюман Дженетик Терапиз, Инк. filed Critical Шайр Хьюман Дженетик Терапиз, Инк.
Publication of EA201892249A1 publication Critical patent/EA201892249A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Настоящее изобретение предусматривает, среди прочего, конъюгированный C1-INH для улучшенного лечения комплемент-опосредованных нарушений, в том числе наследственного ангионевротического отека (HAE). В некоторых вариантах осуществления конъюгированный C1-INH, предусмотренный настоящим изобретением, представляет собой пегилированный C1-INH. В некоторых вариантах осуществления конъюгированный C1-INH, предусмотренный настоящим изобретением, представляет собой C1-INH, конъюгированный с полисиаловой кислотой (PSA).
EA201892249A 2016-04-04 2017-04-04 Конъюгированный ингибитор c1-эстеразы и пути его применения EA201892249A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662318003P 2016-04-04 2016-04-04
PCT/US2017/026001 WO2017176798A1 (en) 2016-04-04 2017-04-04 Conjugated c1 esterase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
EA201892249A1 true EA201892249A1 (ru) 2019-05-31

Family

ID=58632607

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892249A EA201892249A1 (ru) 2016-04-04 2017-04-04 Конъюгированный ингибитор c1-эстеразы и пути его применения

Country Status (22)

Country Link
US (2) US20170360905A1 (ru)
EP (1) EP3439702B1 (ru)
JP (2) JP7173866B2 (ru)
KR (1) KR102569658B1 (ru)
CN (1) CN109310779A (ru)
AU (1) AU2017246404B2 (ru)
BR (1) BR112018070459A2 (ru)
CA (1) CA3019942A1 (ru)
CL (1) CL2018002823A1 (ru)
CO (1) CO2018011586A2 (ru)
CR (1) CR20180497A (ru)
DO (1) DOP2018000218A (ru)
EA (1) EA201892249A1 (ru)
IL (1) IL262044B (ru)
MA (1) MA45473A (ru)
MX (1) MX2018012178A (ru)
PE (1) PE20190375A1 (ru)
PH (1) PH12018502133A1 (ru)
SG (1) SG11201808723UA (ru)
UA (1) UA127374C2 (ru)
WO (1) WO2017176798A1 (ru)
ZA (1) ZA201807056B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092163A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
WO2023280981A1 (en) 2021-07-09 2023-01-12 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2001087922A2 (en) 2000-05-16 2001-11-22 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
CN100404224C (zh) * 2001-01-09 2008-07-23 株式会社市丸技研 加硫后充气处理装置的轮胎夹持装置
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
EP2292271A3 (en) * 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US20060233776A1 (en) * 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
EP1776389B1 (en) 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
EP1896503B1 (en) 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP3412314A1 (en) * 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
KR102071731B1 (ko) * 2011-12-19 2020-01-30 젠자임 코포레이션 갑상선 자극 호르몬 조성물
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
US20150224205A1 (en) * 2012-03-16 2015-08-13 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
CA2892756C (en) 2012-12-07 2020-04-14 Pfizer Inc. Engineered monomeric antibody fragments
TW201505259A (zh) * 2013-07-19 2015-02-01 Chi Mei Comm Systems Inc 天線裝置及無線通訊裝置

Also Published As

Publication number Publication date
EP3439702A1 (en) 2019-02-13
KR20190003546A (ko) 2019-01-09
CO2018011586A2 (es) 2018-11-13
CA3019942A1 (en) 2017-10-12
UA127374C2 (uk) 2023-08-02
NZ747180A (en) 2023-09-29
JP2022118184A (ja) 2022-08-12
MA45473A (fr) 2019-02-13
CN109310779A (zh) 2019-02-05
KR102569658B1 (ko) 2023-08-22
US20180333473A1 (en) 2018-11-22
IL262044A (en) 2018-11-29
AU2017246404A1 (en) 2018-11-01
MX2018012178A (es) 2019-02-07
SG11201808723UA (en) 2018-11-29
AU2017246404B2 (en) 2023-03-09
DOP2018000218A (es) 2018-10-31
WO2017176798A1 (en) 2017-10-12
ZA201807056B (en) 2023-05-31
CL2018002823A1 (es) 2018-11-16
PH12018502133A1 (en) 2019-09-23
EP3439702B1 (en) 2023-09-20
US20170360905A1 (en) 2017-12-21
JP7173866B2 (ja) 2022-11-16
IL262044B (en) 2022-03-01
JP2019513724A (ja) 2019-05-30
CR20180497A (es) 2019-03-04
PE20190375A1 (es) 2019-03-08
BR112018070459A2 (pt) 2019-02-12

Similar Documents

Publication Publication Date Title
EA201892249A1 (ru) Конъюгированный ингибитор c1-эстеразы и пути его применения
CY1125436T1 (el) Αναστολεις dna-pk
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
EA201992209A1 (ru) Модифицированные циклические динуклеотидные соединения
EA201791775A1 (ru) Цистеиновая протеаза
CL2020002444A1 (es) Usos de un inhibidor de masp-2 para proteger un riñón de nefropatía fármaco-inducida (divisional de la solicitud no. 201801817)
EA201990033A1 (ru) Вариантные аденоассоциированные вирусы и способы их применения
MX2021012589A (es) Derivados de piperidina como inhibidores de proteasa especifica de ubiquitina 7.
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE485359T1 (de) Verwendung von grenzflächenaktiven, nicht- enzymatischen proteinen für die textilwäsche
BR112012028467A2 (pt) composições e métodos que compreendem variantes de subtilisina
BR112016005286A2 (pt) composições e métodos compreendendo variantes de protease do clado lg12
EA201791773A1 (ru) Цистеиновая протеаза
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
EA201691794A1 (ru) Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил